eScreen, based in Overland Park, KS, deploys a well-regarded automated platform and FDA-authorized reader for the gathering, handling and reporting of non-regulated and regulated urine drug screens.

With this approval, drug tests for each of the DOT administrations and agencies can now be processed with the same efficient eCCF that non-regulated companies have been using for well over a decade.

Immuno-oncology company Imugene Ltd. has acquired a worldwide exclusive license to Precision Biosciences Inc.’s allogeneic CD19 CAR T-cell therapy program in a... With a U.S. biotech identified as One ...

Health-care products company Alere Inc. said it will acquire eScreen Inc. for $270 million in a deal that will expand the company's presence in the global toxicology market. Carlyle Group was an ...